LivaNova Appoints Keyna Skeffington As Senior Vice President And General Counsel
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the appointment of Keyna Skeffington as senior vice president and general counsel.
Skeffington’s career spans nearly three decades and includes a variety of senior legal counsel roles. She most recently served as vice president of legal – corporate and securities, deputy general counsel and assistant secretary at Medtronic PLC.
“Keyna Skeffington brings a wealth of knowledge to the LivaNova team,” said Damien McDonald, Chief Executive Officer. “Her extensive background and specific experience in medical devices will be tremendous assets to our legal organization.”
Skeffington is accomplished in many areas, including mergers, acquisitions, joint ventures, outsourcing, intellectual property, corporate governance, risk management and healthcare law.
“LivaNova’s legal team is talented and eager,” said Skeffington. “I look forward to building upon the good work taking place, and supporting the growth plans for the Company.”
Skeffington earned her Juris Doctor degree at Tulane University and holds a Bachelor of Arts degree from Mount Holyoke College.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.livanova.com.